Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Metipranolol is a non-selective beta-adrenergic antagonist (beta-blocker) used primarily in ophthalmic solution form to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It works by blocking both beta-1 and beta-2 adrenergic receptors in the eye, leading to decreased production of aqueous humor and thus lowering intraocular pressure. Metipranolol has little or no effect on pupil size or accommodation and lacks significant intrinsic sympathomimetic activity as well as membrane-stabilizing effects. The drug is rapidly metabolized into desacetylmetipranolol, an active metabolite[1][3][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on metipranolol.